Impact of USA300 Methicillin-Resistant Staphylococcus aureus on Clinical Outcomes of Patients With Pneumonia or Central Line-Associated Bloodstream Infections | Zendy

Fernanda C. Lessa | Zendy; Yi Mu | Zendy; Susan M. Ray | Zendy; Ghinwa Dumyati | Zendy; Sandra N. Bulens | Zendy; Rachel Gorwitz | Zendy; G. E. Fosheim | Zendy; Aaron DeVries | Zendy; William Schaffner | Zendy; Joelle Nadle | Zendy; Kenneth Gershman | Zendy; Scott K. Fridkin | Zendy

Open Access

Impact of USA300 Methicillin-Resistant Staphylococcus aureus on Clinical Outcomes of Patients With Pneumonia or Central Line-Associated Bloodstream Infections

Author(s) -

Fernanda C. Lessa,

Yi Mu,

Susan M. Ray,

Ghinwa Dumyati,

Sandra N. Bulens,

Rachel Gorwitz,

G. E. Fosheim,

Aaron DeVries,

William Schaffner,

Joelle Nadle,

Kenneth Gershman,

Scott K. Fridkin

Publication year - 2012

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cis408

Subject(s) - medicine , staphylococcus aureus , pneumonia , methicillin resistant staphylococcus aureus , staphylococcal infections , pathogen , intensive care medicine , bacteremia , microbiology and biotechnology , antibiotics , immunology , biology , bacteria , genetics

The USA300 methicillin-resistant Staphylococcus aureus (MRSA) strain, which initially emerged as a cause of community-associated infections, has recently become an important pathogen in healthcare-associated infections (HAIs). However, its impact on patient outcomes has not been well studied. We evaluated patients with invasive MRSA infections to assess differences in outcomes between infections caused by USA100 and those caused by USA300.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research